Pulmonary Hypertension (PH) remains a significant clinical challenge, driving continuous research into novel therapeutic agents. The prostacyclin pathway, and specifically the IP receptor, plays a crucial role in regulating pulmonary vascular tone and is a prime target for PH treatments. NS-304 (CAS 475086-01-2), also known as Selexipag, has emerged as a pivotal compound in this area. NINGBO INNO PHARMCHEM CO.,LTD., a dedicated manufacturer in China, is a key provider of this essential research chemical.

NS-304 functions as a prodrug, which is converted in the body to its active metabolite, MRE-269. This metabolite acts as a potent and selective agonist for the IP receptor. Activation of the IP receptor leads to increased levels of cyclic adenosine monophosphate (cAMP), causing vasodilation and inhibiting smooth muscle cell proliferation—both critical mechanisms for mitigating pulmonary artery pressure. The compound's high affinity for the human IP receptor (Ki=20 nM) makes it an ideal candidate for preclinical and clinical investigations into PH.

For researchers focused on pulmonary vascular diseases, having access to high-quality NS-304 is critical. It enables detailed studies on IP receptor signaling, helping to elucidate disease mechanisms and evaluate the efficacy of potential therapies. NINGBO INNO PHARMCHEM CO.,LTD. understands the importance of reliable sourcing. We offer our NS-304 for purchase at competitive rates, ensuring researchers can acquire the quantities needed for their studies without compromising on purity. Our reputation as a trusted NS-304 supplier is built on consistent quality and a commitment to scientific advancement.

Whether you are conducting in vitro assays to understand cellular responses or designing in vivo models to assess therapeutic benefits, NS-304 is an indispensable tool. We encourage researchers and procurement specialists to buy NS-304 from NINGBO INNO PHARMCHEM CO.,LTD. to ensure the integrity of their research data. As a leading pharmaceutical intermediate supplier, we are committed to supporting groundbreaking research in the fight against pulmonary hypertension.